Skip to main content
micro-community-banner
 
  • Saved

made a Post

Identification of a prognostic metabolic gene signature in diffuse large B-cell lymphoma - PubMed

Diffuse large B-cell lymphoma (DLBCL) is a clinically diverse disease. Given the numerous genetic mutations and variations associated with it, a prognostic gene signature that can be related to the ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34128320/

  • Saved

made a Post

Aberrant expression of multiple T cell markers on diffuse large B cell lymphoma: a case report - PubMed

The case presented as a diagnostic dilemma for the pathologist. The predicament lies in classifying it as a B cell lymphoma with an aberrant expression of T cell markers versus ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34129157/

  • Saved

made a Post

Extranucleolar CYCLON Staining Pattern Is Strongly Associated to Relapse/Refractory Disease in R-CHOP-treated DLBCL - PubMed

doi: 10.1097/HS9.0000000000000598. 1 Department of Cytology and Pathology, Grenoble-Alpes University Hospital, Grenoble, France. 2 Institute for Advanced Biosciences, INSERM U1209/CNRS UMR 5309/Grenoble Alpes University, Grenoble, France. 3 Department of Clinical ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34131636/

  • Saved

made a Post

The HCK/BTK inhibitor KIN-8194 is active in MYD88 driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance - PubMed

Activating mutations in MYD88 promote malignant cell growth and survival through HCK mediated BTK activation. Ibrutinib binds to BTKCys481 and is active in B-cell malignancies driven by mutated MYD88. Mutations ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34132782/

  • Saved

made a Post

Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse - PubMed

Although methotrexate (MTX) is the most widely used therapy for central nervous system (CNS) prophylaxis in patients with diffuse large B-cell lymphoma (DLBCL), the optimal regimen remains unclear. We examined ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34135307/

  • Saved

made a Post

56 year old Female with newly diagnosed Richter’s transformation. Stage II-X of neck. Path shows DLBCL arising from CLL. No PMH of significance.

What would be your ..... see more

  • Saved

Commented on 's Post

Allogeneic stem cell transplant in non-Hodgkin lymphomas: Still an indication? - PubMed

Allogeneic hematopoietic cell transplantation (alloHCT) used to play a defined role in the treatment of non-Hodgkin lymphoma (NHL). With the advent of modern targeted molecular therapies and immunotherapies, treatment standards ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34105814/

Show More Comments

  • 1 week
    Key Points • The authors of the current article pondered the conventional role of alloHCT in light of the emergence of modern targeted molecular therapies and immunotherapies for B-cell lymphoma. • “Although Show More
  • Saved

made a Post

Molecular classification of aggressive lymphomas-past, present, future - PubMed

Aggressive large B-cell lymphomas (LBCLs) represent a frequent but clinically and molecularly heterogeneous group of tumors. Technological advances over the last decades prompted the development of different classification schemas to ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34105819/

  • Saved

made a Post

Differential expression of miRNAs as biomarkers for predicting the outcomes of diffuse large B-cell lymphoma patients - PubMed

Background: Diffuse large B-cell lymphoma used to be defined as germinal center B-like and non-germinal center B-like subtypes, associated with different prognoses, but the conventional classification does not meet the ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34109978/

  • Saved

made a Post

EHA Preview: Advances, Outcomes in CAR T-Cell Therapies and Management Challenges

With 5 chimeric antigen receptor (CAR) T-cell therapies approved by the FDA, and 299 agents in the pipeline, it's no surprise that the virtual meeting of the European Hematology Association ..... see more

Source : https://www.ajmc.com/view/eha-preview-advances-outcomes-in-car-t-cell-therapies-and-management-challenges

  • Saved

Commented on 's Post

Comprehensive Characterization of Cachexia-Inducing Factors in Diffuse Large B-Cell Lymphoma Reveals a Molecular Subtype and a Prognosis-Related Signature - PubMed

This study demonstrated that CIFs further contribute to the observed heterogeneity of DLBCL, and molecular classification and a risk signature based on CIFs are both promising tools for prognostic stratification, ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34079795/

Show More Comments

  • 1 week 1 day
    Eye opening article elaborating cachexia factors and importance in dlbcl prognosis
  • Saved

Commented on 's Post

Value of total lesion glycolysis and cell-of-origin subtypes for prognostic stratification of diffuse large B-cell lymphoma patients - PubMed

The TLG, cell-of-origin subtypes, and NCCN-IPI are independent prognostic survival factors in DLBCL patients. Moreover, the revised risk model composed of the number of risk factors (high TLG, non-GCB, and ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34079720/

Show More Comments

  • 1 week 2 days
    This is an interesting retrospective study demonstrating the prognostic value of pet/ct total lesions glycolysis plus disease subtype plus nccn ipi with development of a new score for outcome prediction. Show More
  • Saved

Commented on 's Post

Successful Management of a Patient with Refractory Primary Central Nervous System Lymphoma by Zanubrutinib - PubMed

Primary central nervous system lymphoma (PCNSL) is a rare subtype of extranodal non-Hodgkin lymphoma, and the most frequent histological type is diffuse large B-cell lymphoma (DLBCL). Bruton's tyrosine kinase inhibitor ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34079282/

Show More Comments

  • 1 week 5 days
    Key Points • In the current case report, investigators documented the successful treatment of a 53-year-old patient with refractory primary central nervous system lymphoma (PCNSL) using the small molecule inhibitor zanubrutinib. • Show More
  • 2 weeks 1 day
    Clinically useful article demonstrating that a next gen btki can penetrate cns and treat pcns....
  • Saved

Commented on 's Post

CD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance - PubMed

1 Department of Stomatology, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, People's Republic of China. 2 Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34079334/

Show More Comments

  • 2 weeks
    Cd24 as measured by rna expression seems to correlate positively with outcome in abc subset of DLBCL ...further work should be confirmatory and perhaps identify a readily available test
  • Saved

Commented on 's Post

Baseline 18F-FDG PET textural features as predictors of response to chemotherapy in diffuse large B-cell lymphoma - PubMed

doi: 10.1097/MNM.0000000000001447. Online ahead of print. 1 Department of Nuclear Medicine, University of Health Sciences, Ankara City Hospital Department of Medical Informatics, Middle East Technical University, Informatics Institute Department of ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34075009/

Show More Comments

  • 2 weeks
    Fascinating article showing that suvmax and textural heterogeneity of the tumor are responsible for unsatisfactory frontline treatment results. The study is rather small but if confirmed in a larger Show More
  • Saved

Commented on 's Post

Diagnostic accuracy of pelvic magnetic resonance imaging for the assessment of bone marrow involvement in diffuse large B-cell lymphoma - PubMed

Pelvic MRI is effective for detecting BMinv in DLBCL patients, providing a more accurate indication of PFS than BMB/BMS and PET/CT do. It may ultimately be used to improve the ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34043683/

Show More Comments

  • 2 weeks 5 days
    Key Points • In the current retrospective study, Chinese investigators assessed the efficacy of pelvic magnetic resonance imaging (MRI) in the diagnosis of bone marrow involvement (BMinv) in 171 patients with Show More
  • Saved

made a Post

Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients - PubMed

doi: 10.1136/jitc-2019-000148. 1 Ella Lemelbaum Institute for Immuno Oncology, Sheba Medical Center, Tel Hashomer, Israel. 2 Division of Pediatric Hematology and Oncology, The Edmond and Lily Safra Children's Hospital, Sheba ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/32152221/

  • Saved

made a Post

Association of the Geriatric 8 with treatment intensity and prognosis in older patients with diffuse large B-cell lymphoma - PubMed

Because of the heterogeneity among older patients with diffuse large B-cell lymphoma (DLBCL), the establishment of an easy-to-use geriatric assessment tool is an unmet need. We verified the impact of ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34041751/

  • Saved

made a Post

Dynamic changes in peripheral blood lymphocyte subset counts and functions in patients with diffuse large B cell lymphoma during chemotherapy - PubMed

The absolute counts and functions of CD4 + , CD8 + T cells, which were significantly lower in patients with DLBCL, gradually recovered after effective treatment. Therefore, combined detection of ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34044841/